Skip to main content

We’ve updated our Terms & Conditions and Privacy Policy. By using this site, you agree to these terms.

Geisinger becomes the first member of Risant Health

Dr. David T. Feinberg to unveil new information regarding Geisinger's DNA sequencing community health initiative

DANVILLE, Pa. – David T. Feinberg, M.D., MBA, Geisinger president and CEO, will make a major announcement during his presentation at the HLTH Conference, on May 6 at the Aria in Las Vegas. Dr. Feinberg’s presentation, “What Really Matters,” delves into the importance of DNA sequencing and looks at how genomic codes as well as zip codes can affect a person’s health. 

Capping off the presentation will be a major announcement regarding Geisinger’s next steps when it comes to precision health. 

“We think it’s time to transition our successful genomics program beyond the realm of research and into routine clinical care for all of our patients,” Dr. Feinberg said. 

Geisinger is considered a leader in precision medicine with the success of its MyCode Community Health Initiative, which has enrolled more than 200,000 patient-participants and is delivering medically relevant results to participants and their primary care doctors. Some Geisinger participants have had cancers detected earlier and heart disease identified, allowing doctors to treat these conditions before any clinical symptoms became present.

“We're one of the only organizations taking a population approach to genomics through our MyCode project,” said Dr. Feinberg. “To me, what we’re doing is really anticipatory medicine. It's coming up with medically actionable results and giving that information back to our patients.” 

Geisinger’s pioneering efforts in conducting large-scale DNA sequencing have garnered international recognition. In 2014, Geisinger announced a major collaboration with Regeneron Pharmaceuticals to sequence the DNA of its MyCode participants. Geisinger’s decision in 2013 to report clinically actionable genomic results to research participants was the first large-scale genomics project. Five years later, other large national and international projects are now just getting started.  

“No other health system is doing exome sequencing on this scale, and no one has the experience with clinical reporting of actionable genomic results that we now have,” Dr. Feinberg added. 

HLTH is a four-day event that brings together the most innovative and disruptive companies, ideas, and solutions with those in the industry who are prepared to advance the quality of care, improve patient experience, and revitalize the aging healthcare infrastructure. Dr. Feinberg will deliver his presentation Sunday at 6:20 p.m.
 

About Geisinger
Geisinger is among the nation’s leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the non-profit system generates $10 billion in annual revenues across 134 care sites - including 10 hospital campuses, and Geisinger Health Plan, with 600,000 members in commercial and government plans. The Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,600 employed physicians, Geisinger is among Pennsylvania’s largest employers with an estimated economic impact of $14 billion to the state’s economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country.  Learn more at geisinger.org or connect with us on Facebook, Instagram, LinkedIn and X.

 
Dr. David Feinberg
Geisinger President and CEO Dr. David Feinberg
Content from General Links with modal content